Position
SYNTAX RESEARCH, INC. in Merck & Co., Inc.
Back to the book · All holders of MRK
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $20.8K$105.25 → $120.29
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 4.82K | $506.9K | — | — | — | 0.3% |
| Q1 2026 | 1.38K | $166.1K | $120.29 | $20.8K | −$361.5K | 0.1% |